Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Biontech Company

BNTX
US09075V1026
A2PSR2

Price

102.85
Today +/-
-2.83
Today %
-2.72 %
P

Biontech stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Biontech stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Biontech stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Biontech stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Biontech's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Biontech Stock Price History

DateBiontech Price
10/18/2024102.85 undefined
10/17/2024105.69 undefined
10/16/2024108.39 undefined
10/15/2024107.91 undefined
10/14/2024110.15 undefined
10/11/2024110.19 undefined
10/10/2024108.24 undefined
10/9/2024107.42 undefined
10/8/2024109.55 undefined
10/7/2024110.74 undefined
10/4/2024111.78 undefined
10/3/2024108.60 undefined
10/2/2024107.70 undefined
10/1/2024108.35 undefined
9/30/2024106.65 undefined
9/27/2024105.89 undefined
9/26/2024105.25 undefined
9/25/2024104.02 undefined
9/24/2024105.97 undefined
9/23/2024101.74 undefined

Biontech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Biontech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biontech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biontech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Biontech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Biontech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Biontech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biontech’s growth potential.

Biontech Revenue, EBIT and net profit per share

DateBiontech RevenueBiontech EBITBiontech Net Income
2029e3.62 B undefined0 undefined711.69 M undefined
2028e3.94 B undefined-306.82 M undefined17.44 M undefined
2027e3.37 B undefined-616.4 M undefined-431.77 M undefined
2026e2.85 B undefined-1.31 B undefined-552.45 M undefined
2025e2.75 B undefined-1.16 B undefined-678.6 M undefined
2024e2.73 B undefined-1.07 B undefined-584.11 M undefined
20233.82 B undefined908 M undefined930.3 M undefined
202217.31 B undefined12.3 B undefined9.43 B undefined
202118.98 B undefined14.78 B undefined10.29 B undefined
2020482 M undefined-82 M undefined15 M undefined
2019109 M undefined-182 M undefined-179 M undefined
2018128 M undefined-54 M undefined-48 M undefined
201762 M undefined-61 M undefined-86 M undefined

Biontech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
0.060.130.110.4818.9817.313.822.732.752.853.373.943.62
-106.45-14.84342.203,837.14-8.78-77.94-28.490.733.4518.5216.93-8.24
83.8789.0683.4987.7684.6682.7084.29------
0.050.110.090.4216.0714.323.22000000
-0.06-0.05-0.18-0.0814.7812.30.91-1.07-1.16-1.31-0.62-0.310
-98.39-42.19-166.97-17.0177.8971.0523.78-39.00-41.98-45.99-18.26-7.76-
-0.09-0.05-0.180.0210.299.430.93-0.58-0.68-0.55-0.430.020.71
--44.19272.92-108.3868,520.00-8.35-90.14-162.8016.10-18.58-21.92-103.944,082.35
-------------
-------------
226226211253260250242.7000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Biontech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Biontech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
2017201820192020202120222023
             
0.170.410.521.352.0714.0716.55
0.010.020.010.1712.387.152.16
498600179.1
461264503440357.7
53785113272280.9
0.190.450.561.6715.0721.9219.53
102116148326520821971.6
00000.020.081.18
0000000
838886110145159804.1
113545861362.5
00016214236164.7
0.190.210.240.650.761.363.48
0.380.650.82.3215.8323.2823.01
             
167193232246246249248.6
0000000
-0.220.070.271.1311.6519.8120.01
0000000
0000000
-0.050.270.51.3811.920.0620.26
534220102160204354
0000000
0.10.080.110.53.192.711.69
0000000
28361303628.1
0.160.130.140.613.482.952.07
0669231172176191
000067639.7
2642549710921791459.2
264260166340456273689.9
0.420.390.30.953.943.222.76
0.370.650.82.3215.8423.2923.02
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Biontech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Biontech's financial health and stability.

Assets

Biontech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Biontech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Biontech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Biontech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-0.09-0.05-0.18-0.1515.0512.951.19
1122343975123183
0000000
-0.01-0.04-0.08-0.1-14.20.254.58
34156122060356-525
122412225
00003.464.220.48
-0.05-0.06-0.2-0.010.8913.585.37
-58-67-71-85-154-363-705
-53-66-77-145-566-35-6,954
51-6-59-412328-6,249
0000000
-238142-67-59-40
0362375753161-876-738
-236538389594-1,419-778
-------
00000-4840
-0.130.240.110.690.4812.18-2.21
-111-126-270-9873613,2144,665.9
0000000

Biontech stock margins

The Biontech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biontech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biontech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Biontech's sales revenue. A higher gross margin percentage indicates that the Biontech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Biontech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Biontech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biontech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biontech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biontech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Biontech Margin History

Biontech Gross marginBiontech Profit marginBiontech EBIT marginBiontech Profit margin
2029e84.29 %0 %19.67 %
2028e84.29 %-7.78 %0.44 %
2027e84.29 %-18.27 %-12.8 %
2026e84.29 %-46.03 %-19.41 %
2025e84.29 %-41.99 %-24.67 %
2024e84.29 %-39.01 %-21.39 %
202384.29 %23.78 %24.36 %
202282.7 %71.05 %54.5 %
202184.66 %77.89 %54.24 %
202087.76 %-17.01 %3.11 %
201983.49 %-166.97 %-164.22 %
201889.06 %-42.19 %-37.5 %
201783.87 %-98.39 %-138.71 %

Biontech Stock Sales Revenue, EBIT, Earnings per Share

The Biontech earnings per share therefore indicates how much revenue Biontech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biontech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biontech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biontech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biontech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biontech Revenue, EBIT and net profit per share

DateBiontech Sales per ShareBiontech EBIT per shareBiontech Earnings per Share
2029e15.22 undefined0 undefined2.99 undefined
2028e16.59 undefined0 undefined0.07 undefined
2027e14.19 undefined0 undefined-1.82 undefined
2026e11.97 undefined0 undefined-2.32 undefined
2025e11.57 undefined0 undefined-2.85 undefined
2024e11.49 undefined0 undefined-2.46 undefined
202315.74 undefined3.74 undefined3.83 undefined
202269.24 undefined49.2 undefined37.74 undefined
202172.99 undefined56.85 undefined39.59 undefined
20201.91 undefined-0.32 undefined0.06 undefined
20190.52 undefined-0.86 undefined-0.85 undefined
20180.57 undefined-0.24 undefined-0.21 undefined
20170.27 undefined-0.27 undefined-0.38 undefined

Biontech business model

BioNTech SE is a German biotech company specializing in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2008 by Ugur Sahin and Özlem Türeci and is headquartered in Mainz. History: BioNTech was established to develop novel treatment options for cancer patients. Originally started as a pure research company, the company has since evolved into a global leader in mRNA-based therapeutics. In recent years, BioNTech has entered into numerous collaborations and partnerships with renowned pharmaceutical companies and other research institutions to strengthen its innovative power and competitiveness. Business model: BioNTech's business model involves developing novel mRNA-based therapeutics for the treatment of cancer and other serious diseases. The company relies on close collaboration with other research institutions and pharmaceutical companies to leverage the latest scientific knowledge and technologies. BioNTech aims to bring its therapeutics to market as quickly as possible to enable more effective treatment for patients worldwide. Divisions: BioNTech is divided into various divisions to optimize its research activities. One of the most important divisions is cancer research, in which the company specifically seeks new treatment options for various types of cancer. BioNTech focuses on the development of personalized cancer immunotherapy tailored to the individual needs of each patient. In this context, the company works closely with other researchers and oncologists to achieve the best possible outcomes. Another important area of BioNTech is vaccine development. The company uses mRNA technology to rapidly and effectively develop vaccines against various infectious diseases. In 2020, BioNTech, together with the US pharmaceutical company Pfizer, brought the first mRNA vaccine against COVID-19 to the market, which has high efficacy and safety. This technology enables rapid response to new pathogens and targeted vaccine development. Products: BioNTech offers a variety of therapeutics and vaccines based on mRNA technology. One of the company's most important products is the mRNA vaccine against COVID-19, which is in use worldwide. In addition, BioNTech develops personalized cancer immunotherapies tailored to the individual characteristics of patients' tumors. Another product of BioNTech is mRNA immunotherapies that can be used for various autoimmune diseases. Conclusion: BioNTech is an innovative biotech company specializing in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. With its business model that relies on collaborations and partnerships, the company is able to rapidly and effectively respond to new challenges while staying scientifically up to date. BioNTech has brought a variety of products to the market in a short period of time that have high efficacy and safety, thereby helping patients worldwide. Answer: BioNTech is a German biotech company that specializes in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. Biontech is one of the most popular companies on Eulerpool.com.

Biontech SWOT Analysis

Strengths

BioNTech has a strong research and development team consisting of highly skilled scientists and experts in the field of biotechnology. This expertise enables the company to develop innovative solutions and make advancements in the biopharmaceutical industry.

The company has established strategic partnerships with pharmaceutical giants such as Pfizer, which provides BioNTech with resources, distribution networks, and access to global markets. This collaboration leverages the strengths of both companies, leading to increased market presence and accelerated commercialization of products.

BioNTech has successfully developed and gained regulatory approval for its mRNA-based COVID-19 vaccine, which has positioned the company as a key player in the fight against the pandemic. This breakthrough achievement has enhanced BioNTech's reputation and increased investor confidence in the company.

Weaknesses

As a relatively young company, BioNTech has a limited product portfolio compared to established competitors in the industry. This narrow product range makes the company susceptible to market fluctuations and increased competition.

BioNTech's reliance on external funding for its research and development activities poses a potential weakness. The company heavily depends on grants, collaborations, and partnerships, which may expose it to financial uncertainties and restricted control over decision-making processes.

Opportunities

The growing demand for personalized medicine and advancements in mRNA technology present significant opportunities for BioNTech. The company can further explore and develop mRNA-based therapies for various diseases, expanding its product pipeline and addressing unmet medical needs.

BioNTech can leverage its expertise in mRNA technology to collaborate with other pharmaceutical companies, universities, and research institutions. By entering into partnerships or licensing agreements, the company can access new markets, diversify its revenue streams, and accelerate the development of innovative therapies.

Threats

Intense competition within the biopharmaceutical industry poses a threat to BioNTech. Established companies and emerging players are investing heavily in research and development, potentially leading to the introduction of competing products that could impact BioNTech's market share.

The regulatory environment and potential changes in government policies related to healthcare and drug approvals could pose risks for BioNTech. Changes in regulations or delays in obtaining regulatory approvals may hinder the company's ability to bring its products to market in a timely manner.

Biontech Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Biontech historical P/E ratio, EBIT multiple, and P/S ratio

Biontech shares outstanding

The number of shares was Biontech in 2023 — This indicates how many shares 242.7 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biontech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biontech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biontech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biontech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biontech dividend history and estimates

In 2023, Biontech paid a dividend amounting to 0 EUR. Dividend means that Biontech distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Biontech provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Biontech’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Biontech's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Biontech Dividend History

DateBiontech Dividend
20222.13 undefined

Biontech dividend payout ratio

In 2023, Biontech had a payout ratio of 5.65%. The payout ratio indicates the percentage of the company's profits that Biontech distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Biontech represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Biontech could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Biontech's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Biontech Payout Ratio History

DateBiontech Payout ratio
2029e5.65 %
2028e5.65 %
2027e5.65 %
2026e5.65 %
2025e5.65 %
2024e5.65 %
20235.65 %
20225.65 %
20215.65 %
20205.65 %
20195.65 %
20185.65 %
20175.65 %
Unfortunately, there are currently no price targets and forecasts available for Biontech.

Biontech latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-2.06 -3.36  (-62.82 %)2024 Q2
3/31/2024-1.11 -1.31  (-18.28 %)2024 Q1
12/31/20232.47 1.9  (-23.04 %)2023 Q4
9/30/2023-0.1 0.67  (782.28 %)2023 Q3
6/30/2023-0.98 -0.79  (19.23 %)2023 Q2
3/31/20230.15 2.05  (1,312.82 %)2023 Q1
12/31/20228.15 9.26  (13.62 %)2022 Q4
9/30/20224.6 6.98  (51.88 %)2022 Q3
6/30/20227.22 6.45  (-10.72 %)2022 Q2
3/31/20229.34 14.24  (52.42 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the Biontech stock

Eulerpool World ESG Rating (EESG©)

81/ 100

🌱 Environment

82

👫 Social

83

🏛️ Governance

77

Environment

Scope 1 - Direct Emissions
866
Scope 2 - Indirect emissions from purchased energy
8,634
Scope 3 - Indirect emissions within the value chain
1,116,523
Total CO₂ emissions
9,500
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees49.9
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Biontech shareholders

%
Name
Stocks
Change
Date
43.76042 % AT Impf GmbH104,049,145-1,563,99812/31/2023
17.00784 % Medine GmbH40,439,542-966,31112/31/2023
3.65445 % Baillie Gifford & Co.8,689,18286,34312/31/2023
2.00339 % PRIMECAP Management Company4,763,453131,49012/31/2023
1.90019 % Temasek Holdings Pte. Ltd.4,518,080012/31/2023
1.65895 % Harding Loevner LP3,944,4743,943,02912/31/2023
1.49248 % Flossbach von Storch AG3,548,66035,44512/31/2023
0.64178 % Wolfgang (Jeggle Helmut)1,525,967012/31/2023
0.57501 % BlackRock Institutional Trust Company, N.A.1,367,19755,38612/31/2023
0.41177 % UBS Asset Management (Switzerland)979,072133,93712/31/2023
1
2
3
4
5
...
10

Biontech Executives and Management Board

Prof. Ugur Sahin57
Biontech Chief Executive Officer, Member of the Management Board
Compensation 6.31 M
Dr. Sierk Poetting49
Biontech Chief Operating Officer, Member of the Management Board
Compensation 2.47 M
Mr. Sean Marett57
Biontech Chief Compliance Officer, Chief Business Officer, Member of the Management Board
Compensation 2.36 M
Mr. Jens Holstein59
Biontech Chief Financial Officer
Compensation 1.74 M
Dr. Oezlem Tuereci55
Biontech Chief Medical Office, Member of the Management Board
Compensation 1.64 M
1
2
3

Biontech Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Siegfried Holding Stock
Siegfried Holding
SupplierCustomer0,54-0,100,500,780,750,83
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,490,260,750,880,200,69
ICON Stock
ICON
SupplierCustomer0,38-0,370,570,770,370,77
Pfizer Ltd /India Stock
Pfizer Ltd /India
SupplierCustomer0,36-0,030,350,780,820,67
Genmab Stock
Genmab
SupplierCustomer0,35-0,550,310,530,780,75
Maravai Lifesciences A Stock
Maravai Lifesciences A
SupplierCustomer0,270,690,250,580,82-
Immunicum Stock
Immunicum
SupplierCustomer0,240,580,190,760,78-0,61
CITIC Stock
CITIC
SupplierCustomer0,220,40-0,06-0,82-0,170,55
Roivant Sciences Stock
Roivant Sciences
SupplierCustomer0,100,100,050,790,70-
4SC Stock
4SC
SupplierCustomer0,100,090,470,880,64-0,48
1
2
3

Most common questions regarding Biontech

What values and corporate philosophy does Biontech represent?

BioNTech SE represents values of innovation, collaboration, and dedication to improving global health. The company's corporate philosophy is centered around leveraging cutting-edge technology and scientific expertise to develop transformative therapies for patients worldwide. BioNTech is committed to delivering groundbreaking solutions in the field of immunotherapy, particularly in the areas of precision cancer medicine and personalized medicine. With its pioneering mRNA technology platform, BioNTech aims to revolutionize how diseases are treated and prevented, ultimately leading to a future where individualized medicine becomes the norm. The company's unwavering commitment to excellence, scientific rigor, and patient-centric approach defines its core values and drives its mission forward.

In which countries and regions is Biontech primarily present?

BioNTech SE, a leading biotechnology company, operates globally to foster breakthrough advancements in immunotherapies for cancer and infectious diseases. The company has a strong international presence and operates primarily in various countries and regions worldwide. BioNTech SE's key operations extend across the United States, Germany, China, and Singapore, among other strategic locations. By collaborating with renowned partners and establishing a robust network, BioNTech SE aims to accelerate the development and commercialization of innovative therapies, contributing to the improvement of global healthcare.

What significant milestones has the company Biontech achieved?

BioNTech SE, a renowned biotechnology company, has achieved significant milestones over the years. Notably, the company successfully developed and gained regulatory approval for its mRNA-based COVID-19 vaccine, in collaboration with Pfizer. This groundbreaking achievement positioned BioNTech as a key player in the global fight against the pandemic. Additionally, BioNTech has made remarkable progress in advancing personalized cancer immunotherapy through the development of individualized mRNA-based cancer vaccines. The company's continuous innovation, partnerships, and successful clinical trials have propelled BioNTech into the forefront of the biotech industry and solidified its position as a leading pioneer in mRNA technology.

What is the history and background of the company Biontech?

BioNTech SE is a biotechnology company founded in 2008 by Özlem Türeci and Uğur Şahin in Mainz, Germany. The company specializes in the development of personalized cancer immunotherapies and individualized mRNA-based drugs. BioNTech became widely recognized for its pivotal role in developing the mRNA-based Pfizer-BioNTech COVID-19 vaccine. With a strong focus on research and development, BioNTech has built a reputation for its innovative approach to tackling various diseases, including cancer and infectious diseases. As a pioneer in mRNA technology, BioNTech continues to drive advancements in the field of precision medicine, leading the way in the fight against diseases worldwide.

Who are the main competitors of Biontech in the market?

The main competitors of BioNTech SE in the market include other leading biotechnology companies such as Moderna Inc., Johnson & Johnson, Pfizer Inc., Novavax Inc., and AstraZeneca Plc. These companies operate in the same space, focusing on developing novel therapeutics and vaccines to address various diseases and medical conditions. BioNTech SE actively competes with these organizations in the field of mRNA technology and immunotherapy to advance medical innovations and improve patient outcomes.

In which industries is Biontech primarily active?

BioNTech SE is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Biontech?

The business model of BioNTech SE revolves around the development and commercialization of transformative therapies for cancer and other serious diseases. The company specializes in individualized immunotherapies and utilizes its proprietary mRNA technology platform to harness the body's immune system to fight against diseases. BioNTech collaborates with various pharmaceutical partners to advance its programs and conduct clinical trials. By leveraging its expertise in mRNA and immunotherapy, BioNTech aims to deliver innovative treatment options to patients worldwide. Through its commitment to research, development, and strategic partnerships, BioNTech strives to shape the future of medicine with its groundbreaking therapies.

What is the P/E ratio of Biontech 2024?

The Biontech P/E ratio is -42.74.

What is the P/S ratio of Biontech 2024?

The Biontech P/S ratio is 9.14.

What is the Quality Investing of Biontech?

The Quality Investing for Biontech is 2/10.

What is the revenue of Biontech 2024?

The expected Biontech revenue is 2.73 B EUR.

How high is the profit of Biontech 2024?

The expected Biontech profit is -584.11 M EUR.

What is the business model of Biontech

BioNTech SE is a German biotechnology company that was founded in 2008 and is headquartered in Mainz. It focuses on the development and production of personalized immunoncological medications for the treatment of cancer and infectious diseases. The company's business model is designed for several sectors. On one hand, BioNTech collaborates with the industry to develop customized therapeutics based on mRNA technology. On the other hand, the company utilizes its expertise to research its own medications, which are marketed in collaboration with external partners. The fundamental principle of mRNA technology at BioNTech is the development of personalized therapeutics that take into account the patient's individual genetic makeup. Specific antigens of the respective tumor are identified and corresponding mRNA molecules are produced. These are then injected into the patient's body to trigger a targeted immune response against the cancer cells. Personalizing the treatment increases its effectiveness and tolerability. BioNTech also pursues various production methods. The production of GMP-compliant mRNA active substances (GMP – Good Manufacturing Practice) is an important focus of the company. For this purpose, BioNTech has established its own production facility in Mainz, which started operating in May 2020 and has high capacities. This production facility is one of the largest mRNA production centers in Europe and is equipped with modern cleanrooms and highly efficient technologies. Product development at BioNTech ranges from preclinical research to clinical studies and drug approval. The company plays a pioneering role in this field and has entered into numerous collaborations with partners in the biopharmaceutical industry. BioNTech also operates several independent products, with a focus on cancer immunotherapy. The company has developed BNT111, a clinical phase I product for the treatment of late-stage tumors. In this case, a specific antigen present on cancer cells is recognized and fought by T cells. In collaboration with the US pharmaceutical company Pfizer, BioNTech has also developed a COVID-19 vaccine. The vaccine is one of the first mRNA-based COVID-19 vaccines approved by the U.S. Food and Drug Administration (FDA). With the COVID-19 vaccine, BioNTech has made a significant contribution to the fight against the global pandemic. In summary, BioNTech is an innovative, research-driven biotechnology company that specializes in personalized cancer immunotherapy. The company has achieved a significant milestone in combating the COVID-19 pandemic in a short period of time and will continue to be an important player in the biopharmaceutical industry in the future.

What is the Biontech dividend?

Biontech pays a dividend of 2.13 EUR distributed over payouts per year.

How often does Biontech pay dividends?

The dividend cannot currently be calculated for Biontech or the company does not pay out a dividend.

What is the Biontech ISIN?

The ISIN of Biontech is US09075V1026.

What is the Biontech WKN?

The WKN of Biontech is A2PSR2.

What is the Biontech ticker?

The ticker of Biontech is BNTX.

How much dividend does Biontech pay?

Over the past 12 months, Biontech paid a dividend of 2.13 EUR . This corresponds to a dividend yield of about 2.07 %. For the coming 12 months, Biontech is expected to pay a dividend of 0 EUR.

What is the dividend yield of Biontech?

The current dividend yield of Biontech is 2.07 %.

When does Biontech pay dividends?

Biontech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biontech?

Biontech paid dividends every year for the past 2 years.

What is the dividend of Biontech?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biontech located?

Biontech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biontech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biontech from 6/17/2022 amounting to 2.132 EUR, you needed to have the stock in your portfolio before the ex-date on 6/2/2022.

When did Biontech pay the last dividend?

The last dividend was paid out on 6/17/2022.

What was the dividend of Biontech in the year 2023?

In the year 2023, Biontech distributed 2.132 EUR as dividends.

In which currency does Biontech pay out the dividend?

The dividends of Biontech are distributed in EUR.

All fundamentals about Biontech

Our stock analysis for Biontech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biontech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.